Breastfeeding-Related Adverse Drug Reactions of Triptans: A Descriptive Analysis Using Four Pharmacovigilance Databases
- PMID: 38563407
- DOI: 10.1089/bfm.2024.0022
Breastfeeding-Related Adverse Drug Reactions of Triptans: A Descriptive Analysis Using Four Pharmacovigilance Databases
Abstract
Objective: Migraine attacks are common in women of reproductive age. Although attacks are often less severe and less frequent during pregnancy, they regularly reoccur shortly after delivery. When first-line analgesic treatment is insufficient, triptans may be used for acute treatment of migraine attacks. Milk levels of occasional triptan use have shown to be low, and no adverse effects in breastfed infants have been reported. However, the available knowledge on the safety of triptans during breastfeeding is still limited. Methods: Four (inter)national pharmacovigilance databases were searched for breastfeeding related adverse drug reactions of triptans. These included the Dutch Pregnancy Drug Register and three databases of spontaneous reports (Netherlands Pharmacovigilance Centre Lareb, the European Medicines Agency [EudraVigilance], and the World Health Organization [VigiBase]). Results: A total of 26 reports on 27 breastfeeding related adverse drug reactions were identified (one report involved two separate adverse drug reactions). These involve three main complaints: painful breasts and/or nipples, painful milk ejection reflex, and a decrease in milk production. Discussion and Conclusion: The hypothesized pharmacological mechanism relates to the serotonin-receptor agonistic properties of triptans. These may lead to vasoconstriction in the breasts and nipples, including the vasculature surrounding the milk ducts and alveoli, and may also influence the hormonal function and levels of prolactin. The reported adverse drug reactions do not negatively impact the overall compatibility of triptans with breastfeeding. However, breastfeeding women may experience them as unsettling. Awareness of these potential adverse drug reactions is essential and should be weighed against the potential adverse effects of (untreated) symptoms of migraine attacks.
Keywords: adverse drug reactions; breastfeeding; drug safety; lactation; migraine; triptans.
Similar articles
-
Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.Cephalalgia. 2021 Jun;41(7):789-798. doi: 10.1177/0333102420983292. Epub 2021 Jan 12. Cephalalgia. 2021. PMID: 33435709
-
Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database.Eur J Clin Pharmacol. 2014 Nov;70(11):1361-6. doi: 10.1007/s00228-014-1738-2. Epub 2014 Sep 4. Eur J Clin Pharmacol. 2014. PMID: 25183382
-
Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.Cephalalgia. 2014 Jan;34(1):5-13. doi: 10.1177/0333102413499649. Epub 2013 Aug 6. Cephalalgia. 2014. PMID: 23921799
-
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.Cochrane Database Syst Rev. 2020 May 18;5(5):CD011505. doi: 10.1002/14651858.CD011505.pub2. Cochrane Database Syst Rev. 2020. PMID: 32421208 Free PMC article.
-
Medication use in the treatment of migraine during pregnancy and lactation.Curr Pain Headache Rep. 2009 Oct;13(5):392-8. doi: 10.1007/s11916-009-0064-3. Curr Pain Headache Rep. 2009. PMID: 19728967 Review.
Cited by
-
Hallmarks of primary headache: part 1 - migraine.J Headache Pain. 2024 Oct 31;25(1):189. doi: 10.1186/s10194-024-01889-x. J Headache Pain. 2024. PMID: 39482575 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical